GENEART Receives Major Contract from Max Planck Institute for Molecular Genetics
News Jun 04, 2009
GENEART AG has received a major order from the Max Planck Institute (MPI) for Molecular Genetics.
GENEART will produce the required genes and gene variants for the project "Mutanom - Systems Biology of Genetic Diseases" funded by the BMBF (Federal Ministry of Education and Research) over the next two years. The expected order volume will be around EUR 300,000.
Goal of the Mutanom project, which includes the Max Planck Institute for Molecular Genetics, the German Cancer Research Center and the Max Delbruck Center for Molecular Medicine as well as partners with expertise in the area of clinical development, is to research the effects of variations (mutations) in the human genotype (genome).
For their research the project partners require a large number of gene variants, which will be rationally designed and then produced by GENEART. Initially, project research will concentrate on those mutations, which are known to be relevant to certain diseases. The knowledge gained is then expected to be used directly for the development of diagnostic and treatment strategies. The Mutanom Project is an integrated network of the medical genome research, which is financed by the National Genome Research Network.
"We are pleased that the MPI for Molecular Genetics selected GENEART for this project. Gene synthesis allows our customers simple and flexible access to any required gene sequence. The knowledge gained from sequencing projects and subsequent analyses using bioinformatics can thus be verified in the lab with only short time lags. GENEART technology thus provides researchers the opportunity to reach goals faster and more cost efficient compared to traditional approaches of molecular biology", said Prof. Dr. Ralf Wagner, CEO and CSO of GENEART AG.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.